At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,738 enrolled
Drug / intervention
losartan potassium (+) hydrochlorothiazidedrug
Likely dose
losartan potassium (+) hydrochlorothiazide 50mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
52 Week Study to Evaluate the Effects of LOSARTAN 50 mg, 100 mg, 100/12.5 mg HCTZ, 100/25 mg HCTZ on Metabolic Parameters, Blood Pressure and Safety in Hypertensive Patients With Metabolic Syndrome
In Brief
A Phase 3 clinical trial evaluating losartan potassium (+) hydrochlorothiazide for Hypertension and Metabolic Disorder. Completed, enrolled 1,738 participants.
Detailed Summary
To determine if a one year treatment Losartan with or without HCTZ at different dosages have an effect on metabolic parameters in patients with hypertension and the metabolic syndrome.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension, Metabolic Disorder
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2005
First PostedOct 2007
Primary CompletionJan 2008
TodayJul 2026
First PostedOct 18, 2007
Enrollment StartSep 1, 2005
Primary CompletionJan 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 18.7 years ago
Interventions
losartan potassium (+) hydrochlorothiazidedrug
All patients received Losartan 50mg at Visit 2 titrated to Losartan 100mg (if target BP not achieved) titrated to Losartan 100mg + HCTZ 12.5mg (if necessary) up to Losartan 100mg + HCTZ 25mg. Duration of treatment was one year.